Within the setting of diabetes, the target blood pressure is <130/80. The topic of target blood pressures has been well-researched, and several large studies have consistently shown that significant improvements in lengthy term cardiovascular and kidney health do not become apparent until blood stress is reduced to this level. For this reason, doctors tend to be very aggressive when devising treatment plans for diabetic sufferers.

Some studies have suggested that certain groups of diabetic sufferers — like those with preexisting kidney problems — benefit most from blood pressures less than 120/80. Data has shown that the risk of cardiovascular problems and further kidney damage approach their lowest measurable values within this range. Because it is difficult to reduce blood pressure to this level, it is a recommendation usually reserved only for specific patients.
Non-Drug Therapy

The official guidelines of both the American Heart Association and the American Diabetes Association state that blood pressures within the range of 130-139/80-89 should first be treated with “non-pharmacologic” (no medicine) options. These options include:

• Weight loss
• Salt restriction
• Dietary changes
• Quitting smoking
• Limiting alcohol intake

In sufferers without diabetes, strict adherence to these rules very often leads to significant drops in blood pressure, enough so that drug therapy may not be needed. While the same can occur in diabetic patients, it is less common, and drug therapy is usually needed. These changes are still worthwhile, though, because they increase the effectiveness of the drug therapy and ultimately lead to better blood pressure manage.

Drug Therapy

Drug therapy is a necessary step for most sufferers at some point during treatment. Vast amounts of research have been done in an effort to determine which drug or drug combination is the “best” for treating high blood pressure in patients with diabetes. Though study results vary slightly, there is a near universal consensus that the best drugs to use within the setting of diabetes are:

• ACE Inhibitors
• Angiotensin Receptor Blockers (ARBs)
• Diuretics (Thiazides)

These drugs specifically address several concerns associated with higher blood pressure within the setting of diabetes including volume expansion, blood vessel stiffness, and kidney damage. Though some doctors initially begin therapy by trying a diuretic on its own, it is more common to begin with an ACE Inhibitor. Ultimately, some ACE Inhibitor / ARB combination is usually the treatment of choice, with a diuretic added if needed. Though this is the most common type of drug treatment, other drugs may be included depending on specific patient factors.

If your doctor chooses to start therapy with a diuretic, be aware that this is not a bad choice, and there is evidence to support this decision in certain types of sufferers. It will be clear very quickly whether the treatment is working or not, and adjustments will be made if necessary.
Follow-Up Care

Whatever the specific treatment being administered, proper follow up care is important to managing the lengthy term success of your therapy. Within the beginning, you’ll likely see your doctor monthly, or even bi-weekly, until an effective plan is in place. Then, many doctors will ask you to come back every three months for the first year. This close follow up is used to track changes in blood pressure and establish a baseline for certain physical parameters like electrolyte levels (potassium and sodium within the blood) and kidney function.

After the first year, your doctor may choose to switch to six month appointments, or might want you to continue on the three-month schedule. If you are asked to continue the three month schedule, this is not a cause for alarm, it just means that much more time is needed to ensure that everything is going as planned. A growing number of doctors are asking all diabetic patients with higher blood stress to come in every three months. Keeping these appointments is important. Treatment is most effective when paired with a schedule of proper follow-up care.

In six weeks of study, the 76-year-old female and male high cholesterol, aged25 79, complete 73 low-fat diet before the baseline. In the beginning of the trial, participants were randomly assigned to the test results of the treatment group and control group of blood and other or cardiovascular disease markers. During the study, the test group gives three and five grams of low molecular weight (LMW) or high molecular weight (HMW) barley glucan (twice daily, then in cereal and juice.

Posttreatment assessment of blood lipids and other CVD biomarkers revealed improvements in low-density lipoprotein (LDL) cholesterol, triglycerides, markers of glycemic control

(glycosylated hemoglobin, HOMA model) and a key marker of inflammation(hs-CRP).

The researchers concluded both doses of LMW and HMW barley beta-glucan improved blood lipids over a six-week treatment period.

Optimum Diabetics Diabetics Health Supplement